“The first clinical trial of an innovative universal influenza vaccine candidate is examining the vaccine’s safety and tolerability as well as its ability to induce an immune response in [...]
One hundred years after the 1918 pandemic, influenza remains a major cause of disease, killing between 290,000 – 650,000 people globally and afflicting millions of others each year. A universal influenza vaccine could protect against all influenza viruses – both seasonal and pandemic strains – saving countless lives.
Shaping a Path Forward
The Global Funders Consortium for Universal Influenza Vaccine Development is a mechanism to bring together major funders of research and development of universal influenza vaccines along with key stakeholders to accelerate progress in the field through creating a common landscape, identifying critical gaps, and coordinating around a common vision.
Facilitating Collaborative Approaches
The Consortium will bring together the latest data and progress in the field of universal vaccine development to maximize the opportunities for impactful and efficient investments going forward.